These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8929121)

  • 41. Azithromycin: 3-day versus 5-day course in the treatment of respiratory tract infections in children. Croatian Azithromycin Study Group.
    Ficnar B; Huzjak N; Oreskovic K; Matrapazovski M; Klinar I
    J Chemother; 1997 Feb; 9(1):38-43. PubMed ID: 9106016
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relative potencies of azithromycin, clarithromycin and five other orally administered antibiotics.
    Barry AL; Fuchs PC; Brown SD
    J Antimicrob Chemother; 1995 Apr; 35(4):552-5. PubMed ID: 7628991
    [No Abstract]   [Full Text] [Related]  

  • 43. Azithromycin treatment of recurrent respiratory tract infections in children.
    Banerjee R; Hersh A; Newman TB
    Pediatr Infect Dis J; 2005 Nov; 24(11):1030; author reply 1030. PubMed ID: 16282955
    [No Abstract]   [Full Text] [Related]  

  • 44. [Cefotaxime (klaforan) in modern therapy of bacterial infections].
    Khess R; Budanov SV
    Antibiot Khimioter; 1996 Mar; 41(3):44-56. PubMed ID: 8967803
    [No Abstract]   [Full Text] [Related]  

  • 45. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Are penicillins still relevant for empirical treatment in contemporary pediatric therapeutics?
    Onalo R; Adeleke IS; Onalo V
    Ann Afr Med; 2013; 12(1):59-60. PubMed ID: 23481000
    [No Abstract]   [Full Text] [Related]  

  • 47. Clarithromycin and azithromycin: new macrolide antibiotics.
    Piscitelli SC; Danziger LH; Rodvold KA
    Clin Pharm; 1992 Feb; 11(2):137-52. PubMed ID: 1312921
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Compliance in antibiotic therapy of respiratory tract infections].
    Karpov OI
    Antibiot Khimioter; 1999; 44(8):37-45. PubMed ID: 10494389
    [No Abstract]   [Full Text] [Related]  

  • 49. In vitro brodimoprim activity on bacterial strains.
    Benoit-Lemercier C; Bergogne-Bérézin E; Joly-Guillou ML
    J Chemother; 1993 Dec; 5(6):435-43. PubMed ID: 8195835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The macrolides: erythromycin, clarithromycin, and azithromycin.
    Alvarez-Elcoro S; Enzler MJ
    Mayo Clin Proc; 1999 Jun; 74(6):613-34. PubMed ID: 10377939
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and effectiveness of azithromycin in the treatment of respiratory infections in children.
    Lakoš AK; Pangerčić A; Gašparić M; Kukuruzović MM; Kovačić D; Baršić B
    Curr Med Res Opin; 2012 Jan; 28(1):155-62. PubMed ID: 22070514
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A survey of antimicrobial drug resistance in respiratory tract pathogens, isolated in a northern Italian teaching hospital between 1990 and 1999.
    Ferrara A; Morosini M; Dos Santos C; Fietta A
    J Chemother; 2002 Dec; 14(6):568-73. PubMed ID: 12583547
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Which patients with respiratory disease need long-term azithromycin?
    Alchakaki A; Cramer C; Patterson A; Soubani AO
    Cleve Clin J Med; 2017 Oct; 84(10):755-758. PubMed ID: 28985171
    [No Abstract]   [Full Text] [Related]  

  • 54. [A trial of the use of rulid, sumamed and makropen in the combined treatment of generalized periodontitis at a stage of exacerbation].
    Tsarev VN; Dmitrieva LA; Filatova NA; Romanov AE; Chekhova NO
    Stomatologiia (Mosk); 1997; 76(5):4-8. PubMed ID: 9411932
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comment: cost-effectiveness of macrolides in lower respiratory tract infections.
    Renz CL; Ashraf T
    Ann Pharmacother; 2000 Oct; 34(10):1206-7. PubMed ID: 11054992
    [No Abstract]   [Full Text] [Related]  

  • 56. [Pyocyanine synthesis by Pseudomonas aeruginosa in chronic airway infection and the effect of erythromycin on its biological activity].
    Sato K; Suga M; Nishimura J; Kushima Y; Muranaka H; Ando M
    Jpn J Antibiot; 1997 Mar; 50 Suppl A():89-91. PubMed ID: 9597453
    [No Abstract]   [Full Text] [Related]  

  • 57. Azithromycin-induced intrahepatic cholestasis.
    Chandrupatla S; Demetris AJ; Rabinovitz M
    Dig Dis Sci; 2002 Oct; 47(10):2186-8. PubMed ID: 12395890
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evolution of a new drug formulation: the rationale for high-dose, short-course therapy with azithromycin.
    Blumer JL
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 3():S143-7. PubMed ID: 16543075
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [I'd rather give azithromycin for three days. That way the patient complies].
    Llor Vilà C
    Aten Primaria; 2003 Apr; 31(7):433-5. PubMed ID: 12735886
    [No Abstract]   [Full Text] [Related]  

  • 60. Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.
    Zheng S; Matzneller P; Zeitlinger M; Schmidt S
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6675-84. PubMed ID: 25155592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.